<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04249544</url>
  </required_header>
  <id_info>
    <org_study_id>Social Decision Making in PD</org_study_id>
    <secondary_id>W81XWH-19-1-0782</secondary_id>
    <nct_id>NCT04249544</nct_id>
  </id_info>
  <brief_title>Social Decision Making in Parkinson's Disease</brief_title>
  <official_title>Cognitive and Neural Mechanisms of Impaired Social Decision-Making in Parkinson's Patients Taking Dopamine Agonists</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Impulsive and compulsive behaviors occur in up to 46% of Parkinson's Disease (PD) patients
      taking dopamine agonist (DAA) medications. While these abnormal social behaviors have been
      studied in other neurodegenerative disorders, the true incidence of social problems, and the
      relationship to dopamine therapy, in PD patients remains unknown. This study is aiming to
      determine if dopamine agonists alter social decision-making and to determine if impaired
      social decision-making relates to dopamine-induced mesolimbic network dysfunction in PD
      patients. The protocol will include a screening visit, and on-DAA visit, and an off-DAA
      visit. For both the on and off DAA visits, participants will continue taking
      Carbidopa-Levodopa, but will withdrawal off of other PD related medications. Both visits will
      include an MRI, fMRI shock task, questionnaires to be filled out by other the participant and
      the caregiver, moral-decision making computer tasks, and the Unified Parkinsons Disease
      Rating Scale (UPDRS) part II and III. For the on-DAA visit, participants will take
      Pramipexole. For the off-DAA visit, participants will receive a placebo. Participants will
      remind blinded to which medication they are receiving that day and will be counterbalanced
      such that all participants will not take the Pramipexole or placebo on the same days.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Impulsive and compulsive behaviors occur in up to 46% of Parkinson's Disease (PD) patients
      taking dopamine agonist (DAA) medications. While these abnormal social behaviors have been
      studied in other neurodegenerative disorders, the true incidence of social problems, and the
      relationship to dopamine therapy, in PD patients remains unknown. This study is aiming to
      determine if dopamine agonists alter social decision-making and to determine if impaired
      social decision-making relates to dopamine-induced mesolimbic network dysfunction in PD
      patients. The protocol will include a screening visit, and on-DAA visit, and an off-DAA
      visit. For both the on and off DAA visits, participants will continue taking
      Carbidopa-Levodopa, but will withdrawal off of other PD related medications to reduce
      circulating drugs and residual drug effects. Both visits will include an MRI, fMRI shock
      task, questionnaires to be filled out by other the participant and the caregiver,
      moral-decision making computer tasks, and the Unified Parkinson's Disease Rating Scale
      (UPDRS) part II and III. For the on-DAA visit, participants will take Carbidopa-Levodopa 1
      hour before the scan and will take 1mg of Pramipexole 1 hour before the scan. For the off-DAA
      visit, participants will take Carbidopa-Levodopa 1 hour before the scan and will take a
      placebo 1 hour before the scan. Participants will remind blinded to which medication they are
      receiving that day and will be counterbalanced such that all participants will not take the
      Pramipexole or placebo on the same days.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change in a harm aversion cognitive moral decision-making task</measure>
    <time_frame>two weeks</time_frame>
    <description>change in harm aversion from off drug visit to on drug visit</description>
  </primary_outcome>
  <primary_outcome>
    <measure>change in blood flow in the ventral striatum per ASL images</measure>
    <time_frame>two weeks</time_frame>
    <description>change in CBF from off drug visit to on drug visit</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Impulsive group, placebo then pramipexole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>half of the impulsive group will first get the placebo on the first day and pramipexole on the second day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Impulsive group, pramipexole then placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>half of the impulsive group will first get the pramipexole on the first day and the placebo on the second day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-impulsive group, placebo then pramipexole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>half of the non-impulsive group will first get the placebo on the first day and the pramipexole on the second day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-impulsive, pramipexole then placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>half of the non-impulsive group will first get the pramipexole on the first day and the placebo on the second day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pramipexole</intervention_name>
    <description>1mg of pramipexole</description>
    <arm_group_label>Impulsive group, placebo then pramipexole</arm_group_label>
    <arm_group_label>Impulsive group, pramipexole then placebo</arm_group_label>
    <arm_group_label>Non-impulsive group, placebo then pramipexole</arm_group_label>
    <arm_group_label>Non-impulsive, pramipexole then placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1mg equivalent of placebo</description>
    <arm_group_label>Impulsive group, placebo then pramipexole</arm_group_label>
    <arm_group_label>Impulsive group, pramipexole then placebo</arm_group_label>
    <arm_group_label>Non-impulsive group, placebo then pramipexole</arm_group_label>
    <arm_group_label>Non-impulsive, pramipexole then placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 45-80

          -  Ability to give informed consent

          -  Idiopathic Parkinson's disease

          -  Currently taking dopamine agonist therapy

          -  Mild symptom severity (Hoehn &amp; Yahr â‰¤ 3)

          -  Disease duration of &lt;12 years

          -  Demonstrated positive response to dopamine therapy

        Exclusion Criteria:

          -  Medications classes that influence GABA concentrations: benzodiazepines,
             cholinesterase inhibitors, antipsychotics, opioids, and MAO inhibitors

          -  History of substance abuse or use of any psychostimulants (other than caffeine) in the
             last 6 months or more than 4 times in lifetime

          -  Current tobacco (or nicotine use) or alcohol intake greater than 8 ounces of whiskey
             or equivalent per week

          -  Comorbid neurological disorders (e.g., stroke, peripheral neuropathy, seizure
             disorder) or history of head trauma (other than a single concussion)

          -  Unstable medical condition, [e.g., diabetes or pulmonary disease, significant medical
             condition, including high blood pressure (systolic B.P. &gt; 135, Diastolic B.P. &gt; 85),
             or any hepatic, renal, cardiovascular, hematological, endocrine or ophthalmological
             condition]

          -  History of major psychiatric illness (including any affective disorder, substance use
             disorder, psychotic disorder, or eating disorder)

          -  Dementia

          -  Deep brain stimulation

          -  Contraindications to 3 Tesla MRI, e.g., extreme obesity, claustrophobia, cochlear
             implant, metal fragments in eyes, cardiac pacemaker, neural stimulator, tattoos with
             iron pigment and metallic body inclusions or other metal implanted in the body

          -  Dyskinesia or tremor that would cause severe motion artifact during MRI scan

          -  Clear indication of secondary gain
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard R Darby, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kaitlyn R Hay, M.S.</last_name>
    <phone>615-875-7403</phone>
    <email>kaitlyn.r.hay@vumc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>James Silverman</last_name>
    <phone>615-875-5778</phone>
    <email>james.silverman@vumc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Kaitlyn Hay, MS</last_name>
      <phone>615-875-7403</phone>
      <email>kaitlyn.r.hay@vumc.org</email>
    </contact>
    <contact_backup>
      <last_name>James Silverman, PhD</last_name>
      <phone>615-875-5778</phone>
      <email>james.silverman@vumc.org</email>
    </contact_backup>
    <investigator>
      <last_name>Richard R Darby, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel O Claassen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>January 28, 2020</study_first_submitted>
  <study_first_submitted_qc>January 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 31, 2020</study_first_posted>
  <last_update_submitted>April 23, 2020</last_update_submitted>
  <last_update_submitted_qc>April 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Richard Darby</investigator_full_name>
    <investigator_title>Assistant Professor of Neurology</investigator_title>
  </responsible_party>
  <keyword>Impulsive behavior</keyword>
  <keyword>Social decision making</keyword>
  <keyword>Moral decision making</keyword>
  <keyword>dopamine agonists</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pramipexole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

